Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Non-Current Debt (2018 - 2025)

Historic Non-Current Debt for Abeona Therapeutics (ABEO) over the last 7 years, with Q3 2025 value amounting to $10.9 million.

  • Abeona Therapeutics' Non-Current Debt fell 2353.93% to $10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.9 million, marking a year-over-year decrease of 2353.93%. This contributed to the annual value of $13.0 million for FY2024, which is N/A changed from last year.
  • Per Abeona Therapeutics' latest filing, its Non-Current Debt stood at $10.9 million for Q3 2025, which was down 2353.93% from $14.0 million recorded in Q2 2025.
  • Abeona Therapeutics' Non-Current Debt's 5-year high stood at $18.1 million during Q1 2024, with a 5-year trough of $1.2 million in Q1 2021.
  • Moreover, its 4-year median value for Non-Current Debt was $9.6 million (2021), whereas its average is $9.1 million.
  • Examining YoY changes over the last 5 years, Abeona Therapeutics' Non-Current Debt showed a top increase of 22415.22% in 2022 and a maximum decrease of 5138.76% in 2022.
  • Abeona Therapeutics' Non-Current Debt (Quarter) stood at $3.8 million in 2021, then increased by 8.75% to $4.2 million in 2022, then surged by 213.16% to $13.0 million in 2024, then decreased by 16.68% to $10.9 million in 2025.
  • Its last three reported values are $10.9 million in Q3 2025, $14.0 million for Q2 2025, and $11.1 million during Q1 2025.